NeuroTherapia, Inc, a US-based clinical-stage company, announced on Tuesday that the European Medicines Agency (EMA) has approved the company's Phase 2 clinical trial of its lead molecule NTRX-07.
In the double-masked, randomised clinical trial, NTRX-07 will be administered to Alzheimer's disease (AD) participants for 28 days.
In addition to monitoring safety, pharmacokinetics and standard measures of clinical efficacy, the trial is also designed to give an indication of target engagement by analysing various biomarkers of neuroinflammation and neuronal function.
CRU Global, a Europe-based CRO, is managing the trial and it will be conducted at sites in Hungary, Poland and and the Czech Republic. Sites are currently completing training for administrating qEEG and P300 ERP recordings, with patient enrolment expected to commence in February.
Johnson & Johnson's nipocalimab granted FTD for treatment of Sjogren's disease
RedHill Biopharma to submit Talicia for UK marketing authorisation
bioMérieux receives FDA clearance for VITEK COMPACT PRO to combat antimicrobial resistance
GRIN Therapeutics' Radiprodil receives Orphan Drug designation
BioArctic receives US FDA orphan drug designation OOPD for exidavnemab
Eneboparatide Shows Positive Results in Phase III Trial for Chronic Hypoparathyroidism
Precision BioSciences secures IND clearance for gene editing therapy targeting chronic hepatitis B
Xeris Biopharma secures FDA approval for Gvoke VialDx as diagnostic aid
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer
ANI Pharmaceuticals secures FDA approval for ILUVIEN label expansion
Korro Bio receives FDA orphan drug designation for KRRO-110
SpliceBio doses first patient in Phase 1/2 ASTRA study of SB-007
Amgen reports positive Phase 3 trial results for UPLIZNA in generalised myasthenia gravis
Femasys receives CE mark approval for FemBloc delivery system in Europe
European Commission approves Rxulti for adolescent schizophrenia treatment